Welcome, and thank you for accessing our Media Room, which is your gateway to relevant information about the HIV Vaccine Trials Network (HVTN). We are a team of people on a scientific journey to find an effective preventive HIV vaccine. Our work is made possible through the commitment of our heroes – individuals, families, and communities around the world who contribute to the success and impact of our work.
On October 21–25 , 2018, HVTN researchers gathered In Madrid, Spain for the HIV Research for Prevention Conference (HIVR4P). Among the science presented were 11 general and 12 late breaker abstracts from HVTN, as well as two satellite sessions — State of the Art of HIV bNAbs for Prevention of HIV Infection, presented by Larry Corey and Myron Cohen, and A Treasure Trove of Clinical Specimens and Data: Mining Research Opportunities with the HVTN, presented by Jim Kublin and Ashley Clayton.
Recent Press Releases
An analysis conducted by the HIV Vaccine Trials Network (HVTN) observed an overall increase in the proportion of racial and ethnic minorities enrolled in Phase 1 and Phase 2A preventive HIV vaccine clinical trials in the United States between 2002 and 2016 compared to 1988 to 2002. The findings were published on December 5, 2018 in Public Health Reports. Read more >
SEATTLE – DECEMBER 20, 2018 – Study participants move HIV vaccine clinical trials forward
The HIV Vaccine Trials Network (HVTN), which is headquartered at the Fred Hutchinson Cancer Research Center, and its partners are conducting two large-scale clinical trials evaluating the safety and efficacy of experimental HIV vaccine regimens as part of a global response to the HIV and AIDS epidemic. Read more >
The HIV Vaccine Trials Network (HVTN), headquartered at Fred Hutchinson Cancer Research Center, joined stakeholders Friday morning at the Embassy Suites in Seattle for the 15th annual Stronger Together: World AIDS Day breakfast to celebrate Seattle’s ongoing leadership in the fight against HIV and AIDS and to recognize World AIDS Day (December 1st). Read more >
Results from a meta-analysis combining information from a variety of nonhuman primate SHIV (simian/human immunodeficiency virus) challenge studies suggest that the concentration of neutralizing HIV antibodies in the bloodstream correlates strongly to protection against SHIV infection. Read more >
Scientific presentations by the HIV Vaccine Trials Network (HVTN) at the HIV Research for Prevention (HIVR4P) conference showed promising early-stage clinical findings that advance the development of DNA vaccines to prevent HIV infection. Read more >
Preliminary evidence presented at the HIV Research for Prevention (R4P) Conference in Madrid, Spain suggests that the composition of the human gut microbiome may inform how well an experimental HIV vaccine can elicit an immune response. Read more >
The precedent-setting AMP Studies--the most advanced clinical trials to test whether an antibody can prevent HIV infection in people--are fully enrolled.
The pair of Phase 2b clinical trials run by the HIV Vaccine Trials Network (HVTN), which is headquartered at Fred Hutchinson Cancer Research Center, and the HIV Prevention Trials Network (HPTN) have enrolled 4,625 participants who are at risk for HIV infection from communities in the United States, Brazil, Peru, Switzerland, and sub-Saharan Africa. Read more >
An HIV Vaccine Trials Network (HVTN)-funded pilot study was conducted in South Africa to test the development and implementation of a basic mobile phone-based tool to collect data from adult participants enrolled in a phase 1/2a, randomized, controlled double-blind trial called HVTN 108. Read more >
Developing an effective HIV vaccine is the “key step forward” we have been pursuing as a global community to halt one of humankind’s most formidable foes. Read more >
Researchers used a dynamic economic mathematical model to show that five-dose series HIV vaccine campaigns rolled out every two years, in the country with the highest number of daily new HIV infections (South Africa), would provide great health benefits and be potentially cost-effective. Read more >
The Nelson Mandela Academic Clinical Research Unit (NeMACRU) in Mthatha, South Africa became part of a network of clinical trial sites that are conducting the largest Phase 2b/3 HIV vaccine efficacy clinical trial in the country. Read more >
An HIV vaccine regimen tested in an early-phase clinical trial elicited robust immune responses that appeared to be stronger than those observed in a landmark 2009 study showing that a vaccine can protect people from HIV infection. These findings from the ongoing Phase I/II HVTN 100 study were published on June 10 in Lancet HIV. Read more >
Neither frequency of alcohol use, binge drinking, marijuana, nor other drug use negatively impacts retention and adherence rates in phase I clinical trials of preventive HIV vaccines. These were the findings revealed in a meta-analysis performed by an HIV Vaccine Trials Network (HVTN) Research and Mentorship Program (RAMP) scholar to assess the patterns of substance use among enrolled participants, and the impact substance use has on retention in phase 1 preventive HIV vaccine clinical trials. Read more >